(174 days)
Not Found
No
The description details a standard immunoassay technology and automated analyzer, with no mention of AI or ML in the device description, intended use, or performance studies.
No.
This device is an in vitro diagnostic tool used for measuring amphetamine in urine, which helps diagnose or monitor rather than treat a condition.
Yes
The "Intended Use / Indications for Use" section explicitly states that the device is "intended strictly for in vitro diagnostic use in clinical laboratories."
No
The device description explicitly states it is a "solid-phase, chemiluminescent enzyme immunoassay for use with the IMMULITE Automated Analyzer," indicating it is a physical assay kit and requires a hardware analyzer, not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states: "It is intended strictly for in vitro diagnostic use in clinical laboratories..."
- Device Description: The description details a "solid-phase, chemiluminescent enzyme immunoassay," which is a common type of in vitro diagnostic test.
- Purpose: The device is designed for the "qualitative measurement of Amphetamine in urine," which is a diagnostic test performed on a biological sample outside of the body.
N/A
Intended Use / Indications for Use
IMMULITE® Amphetamine is a solid-phase, chemiluminescent enzyme immunoassay for use with the IMMULITE Automated Analyzer and designed for the qualitative measurement of Amphetamine in urine. It is intended strictly for in vitro diagnostic use in clinical laboratories, in the context of a program involving an established confirmatory test for amphetamine. A cutoff of 500 ng/mL is used by the IMMULITE Amphetamine assay to identify positive and negative results
Product codes (comma separated list FDA assigned to the subject device)
DKZ
Device Description
IMMULITE® Amphetamine is a solid-phase chemiluminescent enzyme immunoassay for use with the IMMULITE® Automated Analyzer.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
in vitro diagnostic use in clinical laboratories
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Method Comparison: The IMMULITE Amphetamine procedure was compared to DPC's Double Antibody Amphetamine on a total of 160 urine samples from volunteer donors, presumed not to be drug abusers, and from a reference lab. The samples ranged from 200 to approximately 1000 ng/mL. A cutoff of 500 ng/mL was used for both procedures. Relative sensitivity: 100%, Relative Specificity: 98%, Agreement: 98%.
IMMULITE Amphetamine was also compared to GC/MS results on 50 urine samples obtained similarly as above. The samples ranged from 6 to 1816 ng/mL on GC/MS. A cutoff of 500 ng/mL was used for both procedures.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Relative sensitivity: 100%, Relative Specificity: 98%, Agreement: 98%
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.3100 Amphetamine test system.
(a)
Identification. An amphetamine test system is a device intended to measure amphetamine, a central nervous system stimulating drug, in plasma and urine. Measurements obtained by this device are used in the diagnosis and treatment of amphetamine use or overdose and in monitoring levels of amphetamine to ensure appropriate therapy.(b)
Classification. Class II (special controls). An amphetamine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
0
510 (k) Summary Safety and Effectiveness
This summary of safety and effectiveness information has been prepared in accordance with the requirements of SMDA 1990 and 21 CFR Part 807.92.
| Name: | Diagnostic Products Corporation |
|---|---|
| Address: | 5700 West 96th Street |
| Los Angeles, CA 90045 | |
| Telephone Number: | (310) 645-8200 |
| Facsimile Number: | (310) 645-9999 |
| Contact Person: | Edward M. Levine, Ph.D. |
| Director of Clinical Affairs | |
| Date of Preparation: | December 15, 1999 |
| Device Name: | IMMULITE® Amphetamine |
| Trade: | |
| Catalog Number: | LKAM1 (100 tests), LKAM5 (500 tests) |
| CFR: | An amphetamine test system is a device intended to |
| measure amphetamine, a central nervous system | |
| stimulating drug, in plasma and urine. Measurements | |
| obtained by this device are used in the diagnosis and | |
| treatment of amphetamine use or overdose and in | |
| monitoring levels of amphetamine to ensure appropriate | |
| therapy. | |
| Common: | Reagent system for the determination of Amphetamine in |
| urine. | |
| Classification: | Class II device, 91-DKZ (21 CFR 862.3100) |
| Panel: | Toxicology |
| CLIA Complexity | |
| Category: | We believe the category to be moderate, based on previous |
| classification of analogous tests. | |
| Manufacturer | Diagnostic Products Corporation (DPC) |
| 5700 West 96th Street | |
| Los Angeles, CA 90045-5597 |
1
| Establishment
| Registration #: | DPC's establishment Registration No. is 2017183 |
|---|---|
| Substantially Equivalent | |
| Predicate Device: | DPC's Double Antibody Amphetamine (K871696) |
| Description of Device: | IMMULITE® Amphetamine is a solid-phase |
| chemiluminescent enzyme immunoassay for use with the | |
| IMMULITE® Automated Analyzer. | |
| Intended Use of the | |
| Device: | IMMULITE® Amphetamine is a solid-phase |
| chemiluminescent enzyme immunoassay for use with the | |
| IMMULITE Automated Analyzer and designed for the | |
| qualitative measurement of Amphetamine in urine. It is | |
| intended strictly for in vitro diagnostic use in clinical | |
| laboratories, in the context of a program involving an | |
| established confirmatory test for Amphetamine. A cutoff | |
| of 500 ng/mL is used by the IMMULITE Amphetamine | |
| assay to identify positive and negative results. |
Summary and Explanation of the test:
Amphetamine is a potent sympathomimetic amine capable of stimulating the central nervous system. There are two stereoisomers; d-amphetamine is three to four times more potent than I-amphetamine. The main results of an oral dose of amphetamine (10 to 30 mg) are increased alertness and wakefulness, with decreased sense of fatigue; an elevation of mood, concentration and self-confidence; and elation and euphoria. Amphetamine and similar drugs also suppress the appetite, and have been used in weightloss programs.
Amphetamines may be metabolized by p-hydroxylation, N-demethylation, deamination and conjugation. Nevertheless, substantial amounts are excreted unchanged in the urine. This process is influenced by urinary pH. Low amounts are excreted unchanged in alkaline urine, but as much as 80% of a dose can be excreted in acid urine.
2
Technological Comparison to Predicate:
IMMULITE Amphetamine is a solid-phase, chemiluminescent immunoassay. The solid-phase, a polystyrene bead enclosed within a IMMULITE Test Unit, is coated with a monoclonal antibody specific for amphetamine.
The patient sample and alkaline phosphatase-conjugated amphetamine are simultaneously introduced into the Test Unit and incubated for approximately 30 minutes at 37 ℃ with intermittent agitation. During this time, amphetamine in the samples competes with enzyme-labeled amphetamine for a limited number of antibody binding sites on the bead. Unbound enzyme conjugate is then removed by a centrifugal wash, after which substrate is added and the Test Unit is incubated for a further 10 minutes.
The chemiluminescent substrate, a phosphate ester of adamantyl dioxetane, undergoes hydrolysis in the presence of alkaline phosphatase to vield an unstable intermediate. The continuous production of this intermediate results in the sustained emission of light, thus improving precision by providing a window for multiple readings. The bound complex and thus also the photon output, as measured by the luminometer - is inversely proportional to the concentration of amphetamine in the sample. A qualitative result is then obtained by comparing the counts per second (cps) of the patient sample to those of a sample - the Adjustor supplied with the kit - representing the assay's 500 ng/mL cutoff.
DPC's Double Antibody Amphetamine procedure is a competitive radioimmunoassay in which 125I-labeled amphetamine competes with amphetamine in the sample for antibody sites. After incubation for a fixed time, separation of bound from free is achieved by the PEG-accelerated double-antibody method. Finally, the antibody-bound fraction is precipitated and counted. The counts per minute in the sample tube are then compared to the counts per minute of the Positive Amphetamine Reference cutoff.
Performance Equivalence:
Diagnostic Products Corporation asserts that the IMMULITE® Amphetamine produces substantially equivalent results to other commercially marketed amphetamine assays. such as DPC's Double Antibody Amphetamine assay. Each product is designed for the qualitative measurement of amphetamine in urine. Each product is intended strictly for in vitro diagnostic use in the context of a program involving an established confirmatory test for amphetamine and its principal metabolites.
Method Comparison:
The IMMULITE Amphetamine procedure was compared to DPC's Double Antibody Amphetamine on a total of 160 urine samples from volunteer donors, presumed not to be drug abusers, and from a reference lab. The samples ranged from 200 to approximately 1000 ng/mL. A cutoff of 500 ng/mL was used for both procedures.
3
IMMULITE Amphetamine
| DAb Amphetamine | Positive | Negative | |
|---|---|---|---|
| Positive | 32 | 0 | Relative sensitivity: 100% |
| Negative | 3 | 125 | Relative Specificity: 98% |
| Agreement: 98% |
IMMULITE Amphetamine was also compared to GC/MS results on 50 urine samples obtained similarly as above. The samples ranged from 6 to 1816 ng/mL on GC/MS. A cutoff of 500 ng/mL was used for both procedures.
IMMULITE Amphetamine
| GC/MS | Positive | Negative |
|---|---|---|
| Positive | 18 | 4 |
| Negative | 0 | 28 |
Conclusion:
The data presented in this summary of safety and effectiveness is the data that the Food and Drug Administration used in granting DPC substantial equivalence for IMMULITE® Amphetamine.
Eduard Reue
Edward M. Levine, Ph.D. Director of Clinical Affairs
12/17/99
Date
4
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized symbol that resembles three abstract human profiles facing to the right, stacked on top of each other.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
'JAN 2 7 2000
Edward M. Levine, Ph.D. Director of Clinical Affairs Diagnostic Products Corporation 5700 West 96th Street Los Angeles, California 90045-5597
Re: K992632
Trade Name: IMMULITE® Amphetamine Regulatory Class: II Product Code: DKZ Dated: December 17, 1999 Received: December 20, 1999
Dear Dr. Levine:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic OS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
5
Page 2
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
K 992632/5
K992632 510(k) Number (if known): Device Name: IMMULITE® Amphetamine
Indications For Use:
IMMULITE® Amphetamine is a solid-phase, chemiluminescent enzyme immunoassay for use with the IMMULITE Automated Analyzer and designed for the qualitative measurement of Amphetamine in urine. It is intended strictly for in vitro diagnostic use in clinical laboratories, in the context of a program involving an established confirmatory test for amphetamine. A cutoff of 500 ng/mL is used by the IMMULITE Amphetamine assay to identify positive and negative results
Jean
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K992632
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801 109) OR
Over-The-Counter Use
(Optional Format 1-2-96)